SCHEMBL19638014

SCHEMBL19638014

COc1ccc(-c2nc(N)sc2Cl)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MYC P01106 1/20 0.57
WDR5 P61964 1/20 0.57
ALDH1A1 P00352 4/20 0.50
MAPT P10636 4/20 0.50
KDM4E B2RXH2 4/20 0.50
POLB P06746 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
TP53 P04637 1/20 0.50
HSD17B10 Q99714 1/20 0.50
ADORA1 P30542 2/20 0.49
HPGD P15428 1/20 0.49
PKM P14618 1/20 0.48
LMNA P02545 1/20 0.47
XBP1 P17861 1/20 0.47
MAPK1 P28482 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
KMT2A Q03164 1/20 0.46
FBP1 P09467 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19650376 0.83 MYC (0.60) MYCWDR5ALDH1A1MAPTKDM4E
SCHEMBL8067414 0.83 MAPT (0.69) MYCWDR5ALDH1A1MAPTKDM4E
SCHEMBL10120487 0.83 KDM4E (0.59) MYCWDR5ALDH1A1MAPTKDM4E
Hydrochloric Acid SCHEMBL9548025 0.81 KDM4E (0.67) MYCWDR5ALDH1A1MAPTKDM4E
SCHEMBL558439 0.81 ALDH1A1 (0.68) MYCWDR5ALDH1A1MAPTKDM4E
SCHEMBL19638079 0.80 MYC (0.57) MYCWDR5ALDH1A1MAPTKDM4E
SCHEMBL23610362 0.80 NPC1 (0.49) MYCWDR5MAPTSMN1; SMN2NPC1
SCHEMBL10120491 0.79 KDM4E (0.61) MYCWDR5ALDH1A1MAPTKDM4E
SCHEMBL1051684 0.78 PIK3CD (0.44) MYCWDR5ALDH1A1POLBNPC1
SCHEMBL20767251 0.78 ALDH1A1 (0.67) MYCWDR5ALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107207445-B Adenosine A3Modulators of receptors 帕罗生物制药有限公司 2021-03-16 CN disclosed
EP-3248964-B1 THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS PALOBIOFARMA SL (ES) 2019-07-17 EP disclosed
US-10238637-B2 Modulators of the adenosine A3 receptors PALOBIOFARMA, S.L. (ES) 2019-03-26 US disclosed
US-20180263963-A1 MODULATORS OF THE ADENOSINE A3 RECEPTORS PALOBIOFARMA, S.L. (ES) 2018-09-20 US disclosed
EP-3248964-A1 THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS PALOBIOFARMA S.L. (ES) 2017-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180263963-A1 MODULATORS OF THE ADENOSINE A3 RECEPTORS ADORA3, ADORA2A, ADORA1 MYC 4788/4885WDR5 3585/4885ALDH1A1 483/4885
US-10238637-B2 Modulators of the adenosine A3 receptors ADORA3, ADORA2A, ADORA1 MYC 4788/4885WDR5 3585/4885ALDH1A1 483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.